Dr Ruth Payne

MBChB, MSc, PhD, DTMH, MRCP

Clinical Medicine, School of Medicine and Population Health

Senior Clinical Lecturer

r.o.payne@sheffield.ac.uk
+44 114 215 9535

Office: LU114, The Medical School

Full contact details

Dr Ruth Payne
Clinical Medicine, School of Medicine and Population Health
Office: LU114
The Medical School
Beech Hill Road
Sheffield
S10 2RX

Profile

For enquiries please contact - ClinMed-Operational@sheffield.ac.uk

I was appointed as a Senior Clinical Lecturer and Consultant Microbiologist in August 2022. I originally joined the University of Sheffield in 2018 as an NIHR Academic Clinical Lecturer and Honorary SpR in Infectious Diseases and Microbiology.

I graduated from the University of Sheffield Medical School in 2005 and I have worked in Sheffield, New Zealand, Oxford and Nottingham since then. I completed a Masters in Tropical Medicine and International Health in 2011 at the London School of Hygiene and Tropical Medicine, and subsequently worked as a Research Fellow in the blood-stage malaria vaccine group at the Jenner Institute, University of Oxford (2012 - 2016).

This experience has led to my ongoing involvement and research in vaccination, particularly for pathogens that are difficult to control/ eradicate but cause a huge burden of disease such as malaria.

Research interests

For enquiries, please contact – ClinMed-Operational@sheffield.ac.uk

My research interests are in vaccinology and malaria infection. I am particularly interested in looking at the innate responses to vaccination and how these are affected by changes in vaccine regimen or adjuvant.

Publications

Show: Featured publications All publications

Featured publications

Journal articles

Jin J, Tarrant RD, Bolam EJ, Angell-Manning P, Soegaard M, Pattinson DJ, Dulal P, Silk SE, Marshall JM, Dabbs RA , Nugent FL et al (2018) Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells. npj Vaccines, 3(1). View this article in WRRO
Coughlan L, Sridhar S, Payne R, Edmans M, Milicic A, Venkatraman N, Lugonja B, Clifton L, Qi C, Folegatti PM , Lawrie AM et al (2018) Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults. EBioMedicine, 29, 146-154. View this article in WRRO
Payne RO, Silk SE, Elias SC, Miura K, Diouf A, Galaway F, de Graaf H, Brendish NJ, Poulton ID, Griffiths OJ , Edwards NJ et al (2017) Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. JCI insight, 2(21). View this article in WRRO
Payne RO, Silk SE, Elias SC, Milne KH, Rawlinson TA, Llewellyn D, Shakri AR, Jin J, Labbé GM, Edwards NJ , Poulton ID et al (2017) Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies. JCI insight, 2(12). View this article in WRRO
Payne RO, Griffin PM, McCarthy JS & Draper SJ (2017) Plasmodium vivax Controlled Human Malaria Infection – Progress and Prospects. Trends in parasitology, 33(2), 141-150. View this article in WRRO
Rampling T, Ewer KJ, Bowyer G, Bliss CM, Edwards NJ, Wright D, Payne RO, Venkatraman N, de Barra E, Snudden CM , Poulton ID et al (2016) Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP. The Journal of infectious diseases, 214(5), 772-781. View this article in WRRO
Payne RO, Milne KH, Elias SC, Edwards NJ, Douglas AD, Brown RE, Silk SE, Biswas S, Miura K, Roberts R , Rampling TW et al (2016) Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01. The Journal of infectious diseases, 213(11), 1743-1751. View this article in WRRO
Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, Imoukhuede EB, Payne R, Fehling SK, Strecker T , Biedenkopf N et al (2016) A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. The New England journal of medicine, 374, 1635-1646.

All publications

Journal articles

Ramasamy MN, Kelly EJ, Seegobin S, Dargan PI, Payne R, Libri V, Adam M, Aley PK, Martinez-Alier N, Church A , Jepson B et al (2023) Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland. The Lancet Microbe, 4(11), e863-e874.
Shaw RH, Greenland M, Stuart ASV, Aley PK, Andrews NJ, Cameron JC, Charlton S, Clutterbuck EA, Collins AM, Darton T , Dinesh T et al (2023) Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study – a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines. Journal of Infection.
Nielsen CM, Barrett JR, Davis C, Fallon JK, Goh C, Michell AR, Griffin C, Kwok A, Loos C, Darko S , Laboune F et al (2023) Delayed boosting improves human antigen-specific Ig and B cell responses to the RH5.1/AS01B malaria vaccine. JCI Insight, 8(2).
Mentzer AJ, O’Connor D, Bibi S, Chelysheva I, Clutterbuck EA, Demissie T, Dinesh T, Edwards NJ, Felle S, Feng S , Flaxman AL et al (2023) Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection. Nature Medicine, 29(1), 147-157.
Stuart ASV, Shaw RH, Liu X, Greenland M, Aley PK, Andrews NJ, Cameron JC, Charlton S, Clutterbuck EA, Collins AM , Darton T et al (2021) Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. The Lancet.
Swanson PA, Padilla M, Hoyland W, McGlinchey K, Fields PA, Bibi S, Faust SN, McDermott AB, Lambe T, Pollard AJ , Durham NM et al (2021) AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire.. Science Translational Medicine. View this article in WRRO
Zaric M, Marini A, Nielsen CM, Gupta G, Mekhaiel D, Pham TP, Elias SC, Taylor IJ, de Graaf H, Payne RO , Li Y et al (2021) Poor CD4+ T cell immunogenicity limits humoral immunity to P. falciparum transmission-blocking candidate Pfs25 in humans. Frontiers in Immunology, 12.
de Graaf H, Payne RO, Taylor I, Miura K, Long CA, Elias SC, Zaric M, Minassian AM, Silk SE, Li L , Poulton ID et al (2021) Safety and immunogenicity of ChAd63/MVA Pfs25-IMX313 in a phase I first-in-human trial. Frontiers in Immunology, 12, 694759-694759.
Minassian AM, Silk SE, Barrett JR, Nielsen CM, Miura K, Diouf A, Loos C, Fallon JK, Michell AR, White MT , Edwards NJ et al (2021) Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. Med. View this article in WRRO
Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE , Bibi S et al (2021) Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. The Lancet, 397(10277), 881-891. View this article in WRRO
Milne K, Ivens A, Reid AJ, Lotkowska ME, O'Toole A, Sankaranarayanan G, Munoz Sandoval D, Nahrendorf W, Regnault C, Edwards NJ , Silk SE et al (2021) Mapping immune variation and var gene switching in naive hosts infected with Plasmodium falciparum. eLife, 10.
Nielsen CM, Ogbe A, Pedroza-Pacheco I, Doeleman SE, Chen Y, Silk SE, Barrett JR, Elias SC, Miura K, Diouf A , Bardelli M et al (2021) Protein/AS01B vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors. Cell Reports Medicine, 2(3).
Lynch HF, Darton TC, Levy J, McCormick F, Ogbogu U, Payne RO, Roth AE, Shah AJ, Smiley T & Largent EA (2021) Promoting ethical payment in human infection challenge studies. The American Journal of Bioethics. View this article in WRRO
Abaleke E, Abbas M, Abbasi S, Abbott A, Abdelaziz A, Abdelbadiee S, Abdelfattah M, Abdul B, Abdul Rasheed A, Abdul-Kadir R , Abdulmumeen A et al (2021) Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 397(10274), 605-612.
Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE , Bibi S et al (2020) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 397(10269), 99-111. View this article in WRRO
Labbé GM, Miura K, Silk SE, Gu W, Moon JE, Jin J, Payne RO, Fay MP, Dutta S, Long CA & Draper SJ (2019) Harmonization study between three laboratories for expression of malaria vaccine clinical trial IgG antibody ELISA data in µg/mL. Malaria Journal, 18(1). View this article in WRRO
Alanine DGW, Quinkert D, Kumarasingha R, Mehmood S, Donnellan FR, Minkah NK, Dadonaite B, Diouf A, Galaway F, Silk SE , Jamwal A et al (2019) Human antibodies that slow erythrocyte invasion potentiate malaria-neutralizing antibodies. Cell, 178(1), 216-228. View this article in WRRO
Rawlinson TA, Barber NM, Mohring F, Cho JS, Kosaisavee V, Gérard SF, Alanine DGW, Labbé GM, Elias SC, Silk SE , Quinkert D et al (2019) Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody. Nature Microbiology. View this article in WRRO
Jin J, Tarrant RD, Bolam EJ, Angell-Manning P, Soegaard M, Pattinson DJ, Dulal P, Silk SE, Marshall JM, Dabbs RA , Nugent FL et al (2018) Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells. npj Vaccines, 3(1). View this article in WRRO
Rampling T, Ewer KJ, Bowyer G, Edwards NJ, Wright D, Sridhar S, Payne R, Powlson J, Bliss C, Venkatraman N , Poulton ID et al (2018) Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP. npj Vaccines, 3(1). View this article in WRRO
Coughlan L, Sridhar S, Payne R, Edmans M, Milicic A, Venkatraman N, Lugonja B, Clifton L, Qi C, Folegatti PM , Lawrie AM et al (2018) Corrigendum to “Heterologous Two-dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-lasting Cellular Immunity to Influenza Virus A in Healthy Adults” [EBioMedicine 29 (2018) 146–154]. EBioMedicine, 31, 321-321.
Coughlan L, Sridhar S, Payne R, Edmans M, Milicic A, Venkatraman N, Lugonja B, Clifton L, Qi C, Folegatti PM , Lawrie AM et al (2018) Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults. EBioMedicine, 29, 146-154. View this article in WRRO
Payne RO, Silk SE, Elias SC, Miura K, Diouf A, Galaway F, de Graaf H, Brendish NJ, Poulton ID, Griffiths OJ , Edwards NJ et al (2017) Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. JCI insight, 2(21). View this article in WRRO
Payne RO, Silk SE, Elias SC, Milne KH, Rawlinson TA, Llewellyn D, Shakri AR, Jin J, Labbé GM, Edwards NJ , Poulton ID et al (2017) Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies. JCI insight, 2(12). View this article in WRRO
Payne RO, Griffin PM, McCarthy JS & Draper SJ (2017) Plasmodium vivax Controlled Human Malaria Infection – Progress and Prospects. Trends in parasitology, 33(2), 141-150. View this article in WRRO
Rampling T, Ewer KJ, Bowyer G, Bliss CM, Edwards NJ, Wright D, Payne RO, Venkatraman N, de Barra E, Snudden CM , Poulton ID et al (2016) Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP. The Journal of infectious diseases, 214(5), 772-781. View this article in WRRO
Payne RO, Milne KH, Elias SC, Edwards NJ, Douglas AD, Brown RE, Silk SE, Biswas S, Miura K, Roberts R , Rampling TW et al (2016) Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01. The Journal of infectious diseases, 213(11), 1743-1751. View this article in WRRO
Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, Imoukhuede EB, Payne R, Fehling SK, Strecker T , Biedenkopf N et al (2016) A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. The New England journal of medicine, 374, 1635-1646.
Payne R, Forde D, Vedio A, Cope A, Pratt G & Tunbridge A (2013) ‘It's just a virus’ – viral illness in older people: prevention and management. Reviews in Clinical Gerontology, 23(2), 131-141.
Payne R, Darton TC & Greig JM (2009) Systematic telephone triage of possible ‘Swine’ influenza leads to potentially serious misdiagnosis of infectious diseases. Journal of Infection, 59(5), 371-372.
Salkeld J, Themistocleous Y, Barrett JR, Mitton CH, Rawlinson TA, Payne RO, Hou MM, Khozoee B, Edwards NJ, Nielsen CM , Sandoval DM et al () Repeat controlled human malaria infection of healthy UK adults with blood-stage Plasmodium falciparum: Safety and parasite growth dynamics. Frontiers in Immunology, 13.
Payne R () Commentary on 'Payment in challenge studies: ethics, attitudes and a new payment for risk model'. Journal of Medical Ethics.
Fernandez Lynch H, Darton TC, Levy J, McCormick F, Ogbogu U, Payne RO, Roth AE, Shah AJ, Smiley T & Largent EA () Plumbing the Depths of Ethical Payment for Research Participation. The American Journal of Bioethics, 1-4.

Preprints

Nielsen CM, Barrett JR, Davis CL, Fallon JK, Goh C, Michell AR, Griffin CL, Kwok A, Loos C, Darko S , Laboune F et al () Delayed Booster Dosing Improves Human Antigen-Specific IG and B Cell Responses to the RH5.1/AS01 <sub>B</sub> Malaria Vaccine.
Nielsen CM, Barrett JR, Davis CL, Fallon JK, Goh C, Michell AR, Griffin CL, Kwok A, Loos C, Darko S , Laboune F et al () Delayed Booster Dosing Modulates Human Antigen-Specific Ig and B Cell Responses to the RH5.1/AS01 _B Malaria Vaccine.
Lynch HF, Darton T, Largent E, Levy J, McCormick F, Ogbogu U, Payne R, Roth AE, Jefferson Shah A & Smiley T () Ethical Payment to Participants in Human Infection Challenge Studies, with a Focus on SARS-CoV-2: Report and Recommendations.

Teaching interests: I am the deputy director for the DTM&H Preparatory Course in Sheffield, and lead the teaching on malaria for the course. I also teach on Masters programs within the faculty, in addition to clinical teaching.